success survey

Article

Register today on CancerNetwork.com and join our online community of medical professionals. With your free registration you can: - Get unlimited access to news and archives from Oncology and Oncology NEWS International - Receive email newsletters covering the latest oncology news and information - Comment on articles and engage with other healthcare professionals

Register today on CancerNetwork.com and join our online community of medical professionals. With your free registration you can:
- Get unlimited access to news and archives from Oncology and Oncology NEWS International
- Receive email newsletters covering the latest oncology news and information
- Comment on articles and engage with other healthcare professionals

Register now and you'll receive a free online copy of our exclusive book just for physicians - a $20 value!

Achieving Success and Balance
Yes, It Can Be Done. A Physician's Guide to Having It All.

Stressed out? Looking for solutions for efficiency and balance? We can help.
This guide brings you the best of Physicians Practice articles and columns on avoiding burnout and relieving stress, boosting efficiency and increasing revenue, and finding the best way to achieve balance and success.Click here to register now
 

Related Videos
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

ASCO Guideline Issues Updated Systemic Therapy Recommendations in HCC

April 26th 2024
Article

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

April 26th 2024
Article

Researchers from MSKCC have explored the potential of personalized fludarabine dosing, based on population pharmacokinetics, to enhance the outcomes of CD19 CAR T-cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.

New Tocilizumab Workflow Is More Effective for CRS Related to CAR T, Bispecific Antibodies

April 26th 2024
Article

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.

Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.

Loncastuximab Tesirine Combo Is Effective, Safe in R/R Follicular Lymphoma

April 25th 2024
Article

Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.